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Hepatocellular carcinoma (HCC) is a highly prevalent and lethal cancer worldwide; despite the curative treatment for HCC,
the rate of tumor recurrence after hepatectomy remains high. Tumor recurrence can occur early (<2 years) or late (>2 years)
as metastases or de novo tumors. Several tumor factors were associated with HCC recurrence; high hepatitis B virus (HBV)
load is the major risk factor for late recurrence of HCC after resection. Preoperative antiviral therapy improves liver function,
and postoperative reduce HCC recurrence. In this paper, we focus on antiviral treatment to improve the liver function, prevent
recurrence, and lengthen the overall survival for HBV-related HCC.
1.Introduction
Hepatocellular carcinoma (HCC) is one of the major health
problems worldwide, ranking as the third leading cause of
cancer-related mortality in the world, and the second in
China [1]. The annual incidence of HCC in hepatitis B
cirrhoticpatientscanrunashighas3–5%,andone-thirdwill
develop HCC in their lifetime [2]. For patients with hepatitis
Bvirus-relatedHCC(HBV-relatedHCC),early-stagetumors
and preserved hepatic function, liver resection, and liver
transplantation oﬀer the best therapeutic choice. The pal-
liative treatment modalities include transarterial chemoem-
bolization (TACE) and targeted systemic chemotherapy with
sorafenib. Unfortunately, despite the continuing eﬀorts for
the curative treatment HCC with surgical resection, the
rate of tumor recurrence after hepatectomy remains high
(>70% at 5 years), which still limits survival of the patients
[3]. Several factors are reported to be associated with an
increased risk of HCC recurrence after surgical resection,
including tumor characteristics such as multiplicity, size,
and portal invasion, AFP level, PIVKA-II level, and hepatic
functional parameters such as albumin level, PT, and Child-
Pugh class [4, 5]. Recently,accumulating evidence has shown
that a high serum hepatitis B viral (HBV) DNA level is
another risk factor for de novo HCC development in HBV
carriers irrespective of hepatitis activity [6, 7]. Additionally,
some investigators have shown the viral replicative status
of subjects as a predictor of postoperative recurrence of
HCC [8, 9]. Therefore, it was very signiﬁcant and interesting
to investigate of the molecular mechanism of the direct
carcinogenic eﬀect of HBV, and it may help us to clarify
additional therapeutic targets for HCC prevention. However,
in previous studies, the relation between HBV load and the
recurrence of HCC after resection may be confounded by
other major risk factors for recurrence, such as macroscopic
vascular invasion or noncurative resection. In this paper we
review the incidence of HBV-related HCC and its impact on
the prevention of recurrence with antivirus therapy.
2.The IncidenceandSurveillanceof
HBV-Related HCC
Individuals with chronic hepatitis B (CHB) infection have a
risk of developing HCC, that is, 100-fold greater than the
p e r s o n sw h oa r en o ti n f e c t e d[ 10]. Most carriers of CHB,
including Asians, Africans, and a proportion of persons in
Mediterranean countries, acquire the infection at birth or
within the ﬁrst 1 to 2 years after birth [11]. Once chronic2 International Journal of Hepatology
infection is established, complete eradication of the virus is
still not possible, and these patients are facing the risk of
HCC development [10]. Previous longitudinal studies have
shown that genotype B patients have an earlier and more
frequent hepatitis B e antigen (HBeAg) seroconversion than
genotype C patients, [12, 13] indicating that genotype C
patients may have more severe liver disease than genotype
B patients. In addition, genotype C HBV was associated with
increased viral load, and associations of HBV genotype and
viral load with HCC risk were additive. This suggests that
viral load and genotype determination may be important
factors to consider regarding screening program for the
detection of HCC and treatment indication.
In patients with CHB, screening for HCC is necessary
even after clearance of serum hepatitis B surface antigen
(HBsAg) and HBV DNA and remission of hepatitis, espe-
ciallyinthosewithahighantihepatitisBcoreantibody(anti-
HBc) titer [14, 15] because the oncogenic potential due to
occult HBV infection or the integration of HBV DNA is
considered to continue [16]. The earlier the seroconversion
of HBeAg, the better the clinical outcome of HBV carriers. A
single randomized study from China comparing surveillance
and nonsurveillance in HBV patients using periodic serum
AFPandabdominalultrasoundat6-monthintervalsdemon-
strated the beneﬁt of surveillance in terms of reduced mor-
tality [17]. With AFP assays and the development of modern
imaging systems, such as ultrasonography (US), computed
tomography (CT), and magnetic resonance imaging (MRI),
moreandmorehepatitisB-relatedHCCscanbedetectedand
diagnosed and hepatectomy early. However, the prognosis of
HCC remains unsatisfactory, even after curative resection,
yet with recurrence of HBV-related HCC is extremely high
[18], which is also the main cause of death, in addition
to concomitant hepatic decompensation. It has shown that
with the successful implementation of HCC surveillance and
curative treatment, more patients could avoid the risk of
early recurrence and thus survive longer.
3.TheMechanismsofHBV-Related
HCCRecurrence
It is well known that there are two distinct types of
HCC recurrence: tumors grown from dissemination of the
primary tumor and de novo tumors arising from the “ﬁeld
eﬀect” in diseased liver [19, 20]. That is, the latter is
clonally independent from the primary tumor. However,
the mechanism for recurrent carcinogenesis associated with
HBV in the remaining liver in patients who have undergone
curative resection remains unclear. Over the past years,
studies have suggested that high viral load is via direct and
indirectwayswhicharethoughttobeinvolvedforrecurrence
[21]. It is possible that sustained viremia and subsequent
active viral replication may contribute to the carcinogenic
process. Active replication of HBV may initiate malignant
transformation through a direct carcinogenic mechanism by
increasing the probability of viral DNA insertion in or near
proto-oncogenes, tumor-suppressor genes, or regulatory
elements of cellular DNA [22, 23]. The integration of viral
DNA may increase the production of transactivator protein
hepatitis B X antigen, which may promote the neoplasia of
hepatocytes, as well as, bind to the p53 tumor-suppressor
geneanddisruptitsfunctions[24,25].Indirectly,continuing
HBV replication can also induce chronic liver ﬁbrosis and
inﬂammationandmediatealterationintransforminggrowth
factor-beta1 (TGF-β1) and alpha-M production, thereby
leading to carcinogenesis [26, 27].
Imamura proposed a convenient framework to clinically
diﬀe r e n t i a t ee a c ht y p eo fr e c u r r e n c ea s“ e a r l y ”o r“ l a t e ”
r e c u r r e n c eb a s e do nac u t o ﬀ of 2 years after surgery [28].
This framework has made it possible to assess risk factors
for each type of recurrence [29]. For one thing, early
recurrence, which appears within 2 years after surgery, is
associated with tumor-related factors including the presence
of vascular invasion and additional tumor sites besides the
primary lesion (satellite lesion), which is consistent with the
notion that this type of recurrence is tumor dissemination
as a consequence of malignant characteristic of the primary
tumor. For another, late recurrence, which appears more
than 2 years after surgery, is considered to be associated with
theseverityofhepaticinﬂammationandliverdamageclosely
linked to the “ﬁeld eﬀect.” Early intrahepatic recurrence
has poorer prognosis than late intrahepatic recurrence.
Discrimination of these types of recurrence is clinically
important becausethe biologicalbasis producing eachrecur-
rence is diﬀerent, and the following therapeutic intervention
should be considered accordingly [30]. Recently, Kim et al.
reported that persistent viremia is associated with disease-
free survival after 12 months of surgery, suggesting its
association with late recurrence [31]. And Wu et al. also
evaluatedclinicalvariablestogetherwithHBV-relatedfactors
including viral load, genotype, and recurrent mutations, for
their prognostic implication with respect to early and late
recurrence in 193 HBV-related HCC patients [9]. During
the median followup of 5 years, 134 patients (69%) had
HCC recurrence [19]. It was found that tumor-related
factors: microvascular invasion, positive cut margin, and
high serum AFP level were associated with the risk of
earlyrecurrence,whereasliverinﬂammation/damage-related
factors: histological inﬂammation and ICG-15 retention rate
wereindependentlyassociatedwiththeriskoflaterecurrence
[9]. Interestingly, the high HBV viral load was found to be
associated with the risk of late, but not early recurrence,
probably because the high HBV DNA level is the most
functional measure reﬂecting the exposure to the direct
carcinogenic eﬀect of HBV.
4. The Necessity of AntiviralTreatment on
HBV-Related HCC
As above mentioned, for patients with CHB, serum HBV
DNA levels have emerged as the key risk factor for the
development of HCC. This may argue for an earlier antiviral
intervention, before the development of cirrhosis, to prevent
HCC development, and even more, as adjuvant therapy after
the resection HCC for the patients with a high HBV DNA
level to prevent late recurrence. But only a few recent studies
have evaluated HBV replication status as a predictor of HCC
recurrence [8, 32], and the interpretation of their results wasInternational Journal of Hepatology 3
complicated by the use of antiviral therapy. Notably, several
studies found a signiﬁcant association between high HBV
load and increased risk of HCC and liver cirrhosis [6, 33].
Elevations in serum HBV DNA level are not only a major
risk factor for HCC recurrence, but also the risk factor most
amenable to modiﬁcation.
Several large cohort studies from China, Taiwan, and
Senegal reported that high serum HBV DNA levels at the
time of enrollment were associated with an increased risk of
cirrhosis and HCC. Therefore, it was suggested that serum
HBV DNA level, and not only liver disease activity, might
be used as an indication for antiviral therapy. In a large
prospective study of 3653 HBV carriers in Taiwan, Chen
and colleagues [6] reported that 164 had HCC after a mean
follow-up of 11.4 years. The incidence of HCC correlated
with serum HBV DNA level at entry in a dose-response
relationship. The authors concluded that high serum HBV
DN Alevels(>104 copies/mL)wereastrongpredictorofHCC
independent of HBeAg, ALT, and the presence of cirrhosis.
Moreover, a subanalysis showed that spontaneous decline
of viremia levels from levels higher than 105copies/mL to
levels below 104 copies/mL was associated with a reduced
risk of HCC development by comparison with patients who
maintained high viremia levels. Thus, the authors emphasize
that eﬀective control of HBV replication with antiviral
therapy may lower the risk of HCC.
4.1. The Impact of Antiviral Therapy on HBV Load for HBV-
Related HCC. Antiviral treatment may render patients with
HBV-related HCC better able to tolerate HCC treatments
and may improve prognosis. However, the eﬃcacy of
antiviral therapy on HBV viral status and underlying liver
function in patients is still unclear. Many questions remain
to be answered in terms of clinical management of CHB to
improve the prevention of HCC late recurrence: (1) can the
correlations between high viral load and HCC recurrence
risk be generalized to all HBV carriers whatever their HBeAg
status, alanine aminotransferase (ALT) levels, and stage of
CHB? and (2) the major clinical question is whether antiviral
therapy can prevent HCC late recurrence. Lin conducted a
study in order to evaluate the eﬀectiveness of IFN-α with
16 HBV patients after medical ablation therapy for primary
tumors [34]. They found that HCC recurred in four of
four (100%) untreated patients and in four of 12 (33.3%)
IFN-α treated patients (P = .0384). They concluded that
IFN-α therapy may reduce HCC recurrence after medical
ablation for primary HCC although the sample size was
too small to reach a ﬁrm conclusion. The Asian Cirrhosis
Lamivudine multicenter randomized controlled trial (RCT)
studyshowedthatlamivudinecanreducediseaseprogression
in HBV-related cirrhosis, including an approximately 50%
decrease in HCC incidence. Such eﬃcacy was achieved
despite the emergence of drug resistance in approximately
50% of cases. In a small study, Hung has reported 72 patients
who underwent HCC resection and found that patients with
viralloadofmorethan2000IU/mLhadasigniﬁcantlyhigher
risk of HCC recurrence after resection [8], with viral load
being the most important correctable risk factor for HCC
recurrence (odds ratio 22.3, 95% CI 3.3–151, P = .001).
However, only 10 patients were treated with lamivudine, and
none of these patients had HCC recurrence compared to
those without antiviral therapy, but this ﬁnding could be
due to the small sample size. Recently, a nonrandomized
comparative study for postoperative antiviral treatment was
conducted on patients who underwent curative hepatectomy
for advanced HCC [35]. Patients in the treatment group
(n = 43) received lamivudine with or without adefovir
dipivoxil, while the control group (n = 36) received no
antiviral treatment. The treatment group had a signiﬁcantly
higher HBeAg seroconversion rate (57.2% versus 5.6%; P<
.05). And HBV DNA suppression rates at 12 and 24 months
were 87.2% and 98.0%, respectively, in the treatment group,
compared with 2.8% and 3.6%, respectively, in the control
group (P<. 05). The data of this study has shown the
eﬃcacyofpostoperativeantiviraltherapyinsuppressingviral
replication. Thus, to improve the liver function, antiviral
therapy should be initiated in patients with detectable
serum HBV DNA level after resection. Further RCTs with
larger numbers of patients and longer follow-up periods are
urgently necessary to clarify whether the eﬃcacy of antiviral
therapy on HBV load for HBV-related HCCs’ patients who
underwent hepatectomy.
4.2. The Impact of Antiviral Therapy on Perioperative Liver
Function for HBV-Related HCC. Recent reports found that
an eﬀective preoperative anti-HBV therapy could contribute
to improve liver function. Thia reported the incidence of
postoperative HBV and exacerbation of chronic hepatitis
B( E C H B )[ 36], that transient elevation of serum ALT in
the ﬁrst week after resection occurred in 92% of cases and
resolved by the second week. The peak serum ALT was
222.0IU/L and declined by week 2 after resection. The serum
activities of AST and ALT were signiﬁcantly higher in the
patients with a high viral load than in those with a low
viral load (P = .0005 and P = .0089, resp.) [37]. Notably,
the AST and ALT activities were signiﬁcantly higher in the
patients with a high viral load, and the percentage of patients
with moderately or severe active hepatitis was signiﬁcantly
higherinthepatients withahighviralload. Apreviousstudy
indicatedthatreoperativeprealbuminwas223.7 ±56.0mg/L
versus226.1 ±60.5mg/L(P = .859),albumin/globulinratio
was 1.4 ± 0.2 versus 1.3 ± 0.2 (P = .129), and γ-globulin
on protein electrophoresis was 20.0 ± 4.3 versus 20.6 ± 4.4,
in the treatment and the control groups respectively (P =
.540) [35]. There were no signiﬁcant diﬀerences between
the two groups, and at the sixth postoperative month of
followup, prealbumin was 201.3 ± 52.4mg/L versus 224.3
± 85.8mg/L (P = .148), and albumin/globulin ratio was
1.3 ± 0.3 versus 1.2 ± 0.3 (P = .114). By analysis, there
was no correlation between prealbumin and logarithmic
diﬀerence in HBV DNA level (P = .688), and between
albumin/globulin ratio and logarithmic diﬀerence in HBV
DNA level (P = .130). However, the treatment group had
a signiﬁcantly greater increase in residual liver volume per
unitsurfaceareafollowinghepatectomy(78.0 ±40.1cm3/m2
versus35.8 ±56.0cm3/m2)atthesixthpostoperativemonth.
these results indicated that remnant liver functions in the
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in the control group. Remnant liver function is an important
factor in selecting further treatment for HCC recurrence and
isaprognosticfactorforthesurvivalrate.Therefore,patients
treated by nucleotide analogs have more aggressive therapies
for HCC recurrence, resulting in improving the cumulative
survival rate.
4.3. The Impact of Antiviral Therapy on Postoperative
Recurrences for HBV-Related HCC. As we all known, pro-
longed suppression of HBV replication with nucleoside or
nucleotide analogs may reduce the risk of HBV-related HCC
development [38]. It aslo may prevent postsugery HCC
recurrence. In a cohort study design, Kim et al. [31]h a v e
reported patients on antiviral therapy at the time of liver
resection. 157 patients were included, among them 89 were
non-viremic and 68 were viremic. the 5-year cumulative
recurrence rate was 73% for viremic group compared to
the non-viremic group by 55% (P = .043). However, in
the previous study [35] we found there was no signiﬁcant
diﬀerence in recurrence rate after surgery in the two groups
(76.7% versus 91.7%; P = .077), after a median follow-
up of 12 months. The median time to recurrence in the
treatment and control groups were 7.0 and 6.0 months,
respectively (P = .072). Indeed, Kuzuya et al. [39] study has
also reported that the cumulative recurrence rates of HCC
after initial and curative treatment for HCC did not decrease
by the administration of nucleotide analog. Consequently,
to conﬁrm the eﬃcacy of nucleotide analogs against the
recurrence of HCC, further studies with a larger number of
patients and longer follow-up period are needed to address
this question.
4.4. The Antiviral Therapy on the Overall Survial for HBV-
Related HCC. Up till now, there have been very few studies
that have documented whether antiviral therapy is beneﬁcial
to the survival after treatment for HCC. In theory, modu-
lation in liver function may not only aﬀect survival directly
but also indirectly by inﬂuencing the patient’s tolerance
to various treatments for recurrence. Miao reported in a
meta-analysisstudythat[40],postoperativeantiviraltherapy
as a whole has been shown to reduce HCC recurrence at
year 1, 2, 3, and 5. Several small sample size of RCT and
NRCTs have evaluated the eﬃcacy and outcome of antiviral
therapies in patients with HBV-related HCC after curative
treatment,however,clinicallymeaningfuldiﬀerencesareless.
In the Kuzuya et al. study [39], no signiﬁcant diﬀerences
regarding the recurrence rates of HCC was found (P =
.622). the cumulative HCC recurrence rates at 1, 2, and
3 years in the lamivudine group were 13.5%, 35.1%, and
35.1%, respectively, while those in the control group were
13.4%, 39.2% and 53.2%, respectively. All 16 patients in the
lamivudine group still alive during their follow-up period,
but six of 33 patients died in the control group. There were
nosigniﬁcantdiﬀerenceswithregardtosurvivalratebetween
the two groups; however, the survival rates in the lamivudine
group tended to be higher than those in the control group
(P = .063).
In the RCT of Liaw et al. study, continuous treatment
withlamivudinehasbeenshowntodelayclinicalprogression
in patients with CHB and advanced ﬁbrosis or cirrhosis
by signiﬁcantly reducing the incidence of hepatic decom-
pensation and the risk of HCC [38]. HCC occurred in
3.9% in the lamivudine group and 7.4% in the placebo
group (hazard ratio, 0.49; P = .047). The previous study
also found that after a median follow-up of 12 months, 41
patientsofthetreatmentgroupand36patientsofthecontrol
group had died [35]. The 1- and 2-year overall survival
rates were 41.9% and 7.0%, respectively, for the treatment
group,and33.3%and0%,respectively,forthecontrolgroup.
(P = .0094) [35]. The 1- and 2-year disease-free survival
rates were 23.3% and 2.3%, respectively, for the treatment
group, and 8.3% and 0%, respectively, for the control group.
(P = .072). The date did not show a signiﬁcant eﬀect of
postoperative antiviral therapy on HCC recurrence, but it
showed a signiﬁcant beneﬁt in overall survival. Although
nucleosideanalogsdidnotreduceshort-termrecurrencerate
or progression of disease, they promoted postoperative viral
clearance, increased residual liver volume, and enhanced
hepatocyte regeneration in HCC patients associated with
active hepatitis B, which signiﬁcantly enhanced the tolerance
to subsequent therapy. As a result, the overall survival was
improved for those patients with postoperative antiviral
therapy. We putative that if compared with other adjuvant
therapies, antiviral therapy may serve as a cost-eﬀective and
favorable alternative to improve the prognosis of patients,
and long-term prospective studies of antiviral therapy in
chronic HBV carriers may aslo be required.
5. Character of AntiviralDrugs
5.1. Interferon. The ﬁrst treatment that had some success
against CHB was interferon alpha (IFN-α). IFN-α has both
antiviral and antiproliferative properties. Meta-analyses have
shown that IFN-a has a beneﬁcial eﬀect on HBeAg loss and
sustained reduction in serum HBV DNA levels [41, 42]. The
antiproliferative eﬀects of IFN include retardation of G1/S
phase transition and inhibition of cell proliferation without
apoptosis [43], and also induction of antiproliferative sig-
naling through the JAK/STAT pathway [44]. However, it is
not clear whether it has potential eﬀect on HCC prevention.
Only one RCT and several case-control or cohort studies
have shown its beneﬁts for preventing HCC, particularly
in cirrhotic patients who responded to therapy. In patients
with decompensated cirrhosis, standard or pegylated INF-
α is usually contraindicated or causes profound intolerance,
but it is still one of the choices for the operative candidates.
5.2. Nucleos(t)ide Analogs. During the last decade, the rise
of oral nucleos(t)ide analogs has changed the treatment
landscape for CHB. Long-term lamivudine treatment can
prevent complications of HBV-related liver disease as long as
viral suppresion is maintained [38]. It is considered to slow
the progression of severe liver disease to cirrhosis as well as
to HCC [38, 45]. However, the overwhelming majority of
patients relapsed after treatment cessation. It could form (as
will other nucleosides with even lower rates of resistance)
the backbone of maintenance combination therapies. The
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of resistance observed in both HBeAg and anti-HBe-positive
HCC patients. The resistance usually emerges after the ﬁrst 6
months with cumulative rates of 15–25% by 12 months and
60–65% by 4 years of therapy [46].
Adefovir dipivoxil and entecavir have been shown to be
safe and eﬀective for the treatment of patients with CHB
that does not respond to lamivudine [47, 48]. It is eﬀective
againstbothwild-typeandlamivudine-resistantHBVstrains
[46]. In the pivotal anti-HBe positive adefovir study [49],
185 patients were randomised to placebo or adefovir 10mg
daily for 48 weeks. At 48 weeks, the adefovir-treated group
had signiﬁcant improvement when compared with placebo
improvement in liver histology (64% versus 33%), reduc-
tionsinHBVDNA(3.91versus1.35logcopies/mL),normal-
isationofALT(72%versus29%),anundetectableHBVDNA
(<400 copies/mL), and HBeAg seroconversion (12% versus
6%). Data from a recent study of 125 patients undergoing
long-term adefovir treatment indicated that 0% of patients
had resistance in year 1, 11% in year 3, and 28% in year 5.
Interestingly, all patients who developed adefovir resistance
were not receiving lamivudine and adefovir combination
therapy, but adefovir monotherapy [50]. Moreover, based on
invitrostudiesandlimitedclinicaldata,lamivudinehasbeen
shown to be eﬀective in patients with adefovir-resistant HBV
[51, 52]. For these reasons above, we deduce that lamivudine
and adefovir combination therapy may be better than
adefovir monotherapy. Because of the suboptimal proﬁle
of both lamivudine and adefovir monotherapy for patients
with HBV-decompensated cirrhosis, a ﬁrst-line combined
indeﬁnite use of lamivudine and adefovir is recommended
in several guidelines, despite the lack of data on eﬃcacy and
safety for such a strategy [53]. Tenofovir is the latest antiviral
medicine and has similar safety proﬁle as adefovir in the
phase III trials.
6.FuturePerspectives
The goal of antiviral therapy for CHB is to prevent the devel-
opment of cirrhosis and HCC. To date, several guidelines for
the treatment of CHB patients are presented. However, there
are no uniform guidelines globally for the usage of antivirals
in the treatment CHB, let alone antivirals on HBV-related
HCC at present. Currently the deﬁnite indications for the
treatment of CHB are serum HBV DNA levels greater than
105 copies/mL and ALT levels more than 2×ULN [54, 55].
According to the American Association for the Study of
Liver Diseases and Asian Paciﬁc Association for the Study of
the Liver guidelines, biopsy-conﬁrmed liver disease is a key
requisite for initiating treatment in patients older than 40
years of age with serum ALT levels between 1 and 2×ULN.
If cirrhosis is present, an HBV DNA level greater than 105
copies/mL is the sole criterion for treatment. Treatment
end points, including reduction of HBV DNA levels to
less than 105 copies/mL, ALT normalization, HBeAg loss,
HBsAg loss, and improvement in liver histology, are used to
determine treatment success. These guidelines may apply to
patients who acquire the HBV infection during adolescence
oradulthoodbutarelesssuitableformostHBVcarriers,who
are infected in early life. In light of the reports, the liver-
related mortality and complications were greater in patients
with ALT levels between 0.5 and 1×ULN than in those with
ALT levels less than 0.5×ULN [56, 57], and the revision of
the ULN for patients with CHB is recommended by some
guidelines [11, 55, 58]. Therefore, HBeAg seroconversion
maynotbeanadequateendpointforthesepatients;theideal
treatment end points are permanent suppression of HBV
DN Atolevelsundetectablebypolymerasechainreactionand
reductionofALTlevelstolessthan0.5×ULN.Inthecurrent
treatment guidelines, antiviral treatments should be started
amongcirrhoticpatientsdespitelowerHBVDNAlevels[59].
Treatment is based on HBV replication status and stage of
liver disease, modulated by the age of the patient, HBeAg
status, and patient preference.
However, results of experimental studies suggest that
early treatment intervention is necessary to prevent liver
cell damage and decrease viral genome integration. Another
important ﬁnding from recent studies is that viral genome
integration persists despite antiviral induced viral suppres-
sion and cccDNA clearance. This was shown to be associated
with the expansion of cellular clones not expressing viral
antigens. Therefore, screening of HCC remains mandatory
even in patients with sustained viral suppression induced
by antiviral therapy to detect HCC for which curative
treatments can be proposed. Late recurrence mostly cor-
responds to de novo carcinogenesis associated with HBV
viremia as well as the “ﬁeld eﬀect” in HBV-related HCC.
This may support prioritized use of anti-HBV treatment
as adjuvant therapy after the resection or ablation of HCC
for the patients with a high HBV DNA level to prevent
late recurrence, given that the incidence rate of recurrence
is higher than that of the initial HCC development [60].
Furthermore, investigation of the molecular mechanism
of the direct carcinogenic eﬀect of HBV may help clarify
additional therapeutic targets in terms of HCC prevention.
Currently, available evidence, mostly obtained from PCR-
based assays with limited scale, has identiﬁed a handful of
the genomic integrations potentially aﬀecting the function
of genes, for example, cyclin A and telomerase reverse
transcriptase, in a sporadic manner [61, 62].
Recently, emerging genomics technology like high-
throughput sequencing [63, 64]m a yp r o v i d eam o r e
comprehensive view of the critical recurrent oncogenic
integration events. Combination of the new sequencing
assaywithchromatinimmunoprecipitation(ChIP-Seq)[65],
may help to identify oncogenic transactivation by HBV
proteins to obtain complementary information of the direct
carcinogenic eﬀect caused by HBV. Although an antineo-
plasm eﬀect is not expected by nucleoside analogues, the
incidence rate of HCC would decrease due to a cessation
of hepatitis. Future RCTs with larger sample size, longer
followup, and regular HBV DNA monitoring will be needed
to substantiate the beneﬁcial eﬀects of antiviral therapies
which where performed in the light of the recently updated
HBV treatment guidelines, on the prognosis of HCC and
HCC recurrence. Of course, they are focusing on the need to
lowerthethresholdofcommencingantiviraltreatmentbased
on HBV-related HCC.6 International Journal of Hepatology
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